Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT03777124 2025-07-04

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Phase 2 Unknown

132 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT06241807 2024-02-14

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Phase 2 Recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04379739 2023-12-06

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

89 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05825443 2023-04-25

PANORAMA

Phase 2 Recruiting

57 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03085069 2023-02-16

A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

Phase 2 Unknown

146 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Respiratory Tract Diseases

NCT04749394 2022-08-16

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

Phase 2 Unknown

42 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05472467 2022-07-25

IMCORT-2

Phase 2 Unknown

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04878107 2022-05-02

SABRE

Phase 2 Unknown

88 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04291092 2021-09-10

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Phase 2 Unknown

63 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04943029 2021-09-02

NEOSUN

Phase 2 Unknown

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04541251 2021-06-23

Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC

Phase 2 Unknown

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04828395 2021-05-11

F&C

Phase 2 Unknown

65 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04102982 2020-11-02

MWA in NSCLC

Phase 2 Unknown

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04303130 2020-03-10

Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

Phase 2 Unknown

52 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03557411 2020-02-05

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

Phase 2 Unknown

42 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04167774 2019-11-22

Compass-001

Phase 2 Unknown

62 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04108013 2019-09-27

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC

Phase 2 Unknown

38 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

PANORAMA

A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

IMCORT-2

SABRE

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

NEOSUN

Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC

F&C

MWA in NSCLC

Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

Compass-001

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC